Free tool
FAERS Monitor: Harvoni
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205834 or its brand name (Harvoni, Ledipasvir, Sofosbuvir). Reports on generic versions are filed under their own applications.
Reports
19,121
Serious
7,455
39% of reports
Hospitalization
2,708
Death reported
780
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue4,131
- headache3,707
- nausea1,242
- drug ineffective1,140
- diarrhoea913
- hepatitis c887
- insomnia835
- vomiting442
- dizziness440
- drug dose omission436
- hepatocellular carcinoma402
- treatment failure374
- rash362
- asthenia338
- arthralgia330
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 125 |
| 2015 | 4,134 |
| 2016 | 5,147 |
| 2017 | 4,537 |
| 2018 | 2,885 |
| 2019 | 1,344 |
| 2020 | 414 |
| 2021 | 221 |
| 2022 | 160 |
| 2023 | 68 |
| 2024 | 34 |
| 2025 | 24 |
| 2026 | 26 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis cSignal | 887 | 87.1 | 81.5 | 69,946 |
| hepatocellular carcinomaSignal | 402 | 61.3 | 55.5 | 22,551 |
| headacheSignal | 3,707 | 6.5 | 6.3 | 17,807 |
| fatigueSignal | 4,131 | 5.9 | 5.7 | 17,204 |
| treatment failureSignal | 374 | 5.0 | 4.5 | 1,186 |
| insomniaSignal | 835 | 3.5 | 3.2 | 1,469 |
| drug dose omissionSignal | 436 | 2.9 | 2.6 | 546 |
| nausea | 1,242 | 1.7 | 1.6 | 394 |
| diarrhoea | 913 | 1.6 | 1.5 | 187 |
| vomiting | 442 | 1.0 | 0.9 | 0 |
| asthenia | 338 | 1.0 | 0.9 | 0 |
| dizziness | 440 | 1.0 | 0.9 | 0 |
| drug ineffective | 1,140 | 1.0 | 0.9 | 3 |
| rash | 362 | 0.9 | 0.8 | 3 |
| arthralgia | 330 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.